{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:51:41Z","timestamp":1793065901432,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008161.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000}}],"reference-count":204,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008161.pub3","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T08:44:36Z","timestamp":1689237876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["First-line diuretics versus other classes of antihypertensive drugs for hypertension"],"prefix":"10.1002","volume":"2023","author":[{"given":"Marcia","family":"Reinhart","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology & Therapeutics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorri","family":"Puil","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology & Therapeutics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M","family":"Salzwedel","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology & Therapeutics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology & Therapeutics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"10.1002\/14651858.CD008161.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"42","author":"ALLHAT Group","year":"2003","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"A1460","DOI":"10.1016\/S0735-1097(15)61460-7","article-title":"Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT STUDY","volume":"1","author":"Bang","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1524-6175.2004.03216.x","article-title":"Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study","volume":"6","author":"Barzilay","year":"2004","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","article-title":"Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"166","author":"Barzilay","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diacare.24.4.654","article-title":"Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"24","author":"Barzilay","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc07-1452","article-title":"Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"31","author":"Black","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1751-7176.2008.00015.x","article-title":"Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"10","author":"Cushman","year":"2008","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-137-5_Part_1-200209030-00006","article-title":"Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. [Summary for patients in Ann Intern Med. 2002 Sep 3;137(5 Part 1):I38; PMID: 12204046]","volume":"137","author":"Davis","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group","volume":"9","author":"Davis","year":"1996","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"A16491","DOI":"10.1161\/circ.130.suppl_2.16491","article-title":"Predictors of incident conduction system disease in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"130","author":"Dewland","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1751-7176.2009.00149.x","article-title":"Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?","volume":"11","author":"Grimm","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.HYP.37.1.19","article-title":"Baseline Characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"37","author":"Margolis","year":"2001","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)","volume":"54","author":"Haywood","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11606-008-0515-2","article-title":"Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"23","author":"Heidenreich","year":"2008","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jch.12290","article-title":"Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"16","author":"Muntner","year":"2014","journal-title":"Journal of Clinical Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1468-6708-3-10","article-title":"Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone","volume":"3","author":"Piller","year":"2002","journal-title":"Trials"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s11606-014-2947-1","article-title":"Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT","volume":"1129","author":"Piller","year":"2014","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/sim.5580","article-title":"How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?","volume":"32","author":"Proschan","year":"2013","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/HJH.0000000000000204","article-title":"Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT","volume":"32","author":"Reisin","year":"2014","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/str.46.suppl_1.wp172","article-title":"Baseline quality of life and risk of stroke in the antihypertensive and lipid lowering to prevent heart attack (ALLHAT) trial","volume":"46","author":"Shams","year":"2015","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group","volume":"283","author":"The ALLHAT Officers","year":"2000","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Dunn","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Harris-Haywood","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jash.2014.08.003","article-title":"Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT","volume":"8","author":"Yamal","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.hjh.0000220409.69116.2e","article-title":"Cost implications of development of diabetes in the ALPINE study","volume":"24","author":"Lindholm","year":"2006","journal-title":"Journal of Hypertension - Supplement"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ajh\/hpt212","article-title":"Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study","volume":"27","author":"Chowdhury","year":"2014","journal-title":"American Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD008161.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","article-title":"Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide","volume":"220","author":"Berglund","year":"1986","journal-title":"Acta Medica Scandinavica"},{"issue":"8223","key":"10.1002\/14651858.CD008161.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(81)92624-6","article-title":"beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects","volume":"1","author":"Berglund","year":"1981","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0037|cit37","first-page":"354","article-title":"Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands","volume":"60","author":"Hoogerbrugge","year":"2002","journal-title":"Netherlands Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/S1520-765X(01)90053-7","article-title":"Principal results from the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"3","author":"Brown","year":"2001","journal-title":"European Heart Journal Supplements"},{"issue":"9227","key":"10.1002\/14651858.CD008161.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004872-200401000-00023","article-title":"Large artery wall thickening and its determinants under antihypertensive treatment: the IMT-INSIGHT study","volume":"22","author":"Gariepy","year":"2004","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/080370502321095294","article-title":"The role of the critical event committee in a major cardiovascular outcome study","volume":"11","author":"Heagerty","year":"2002","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.HYP.0000057420.27692.AD","article-title":"Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)","volume":"41","author":"Mancia","year":"2003","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00004872-200203000-00032","article-title":"Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"20","author":"Mancia","year":"2002","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/08037050410022954","article-title":"Effects of nifedipine GITS and diuretics in isolated systolic hypertension--a subanalysis of the INSIGHT study","volume":"13","author":"Mancia","year":"2004","journal-title":"Blood Pressure"},{"issue":"7","key":"10.1002\/14651858.CD008161.pub3-BIB0046|cit46","first-page":"401","article-title":"The effect of nifedipine GITS on outcomes in patients with previous myocardial infarction: a subgroup analysis of the INSIGHT study","volume":"9","author":"Mancia","year":"2002","journal-title":"British Journal of Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1161\/01.CIR.103.24.2949","article-title":"Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes","volume":"103","author":"Simon","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0048|cit48","first-page":"527","article-title":"Nifedipine, hypertension, and arterial wall thickness in extracoronary arteries: design features of a clinical trial using non invasive ultrasound end points","volume":"28","author":"Simon","year":"1996","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/01.CIR.98.2.140","article-title":"Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents","volume":"98","author":"Gottdiener","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo","volume":"328","author":"Materson","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","article-title":"Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial","volume":"276","author":"Borhani","year":"1996","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/diacare.21.12.2103","article-title":"Isradipine in prediabetic hypertensive subjects","volume":"21","author":"Byington","year":"1998","journal-title":"Diabetes Care"},{"issue":"6488","key":"10.1002\/14651858.CD008161.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party","volume":"291","author":"Medical Research Council Working Party on Mild Hypertension","year":"1985","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0054|cit54","first-page":"616","article-title":"Results of MRC (UK) trial of drug therapy for mild hypertension","volume":"10","author":"Peart","year":"1987","journal-title":"Clinical and Investigative Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008161.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/HJH.0b013e3283568a73","article-title":"The predictive ability of blood pressure in elderly trial patients","volume":"30","author":"Carr","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results","volume":"304","author":"MRC Working Party","year":"1992","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes","volume":"22","author":"Marre","year":"2004","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amjhyper.2006.05.018","article-title":"Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes","volume":"20","author":"Puig","year":"2007","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1291\/hypres.24.475","article-title":"Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH","volume":"24","author":"Kuwajima","year":"2001","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0060|cit60","first-page":"29","article-title":"Randomized double-blind comparison of a calcium channel blocker and a diuretic in elderly hypertensives: a final result of the National Interventional Cooperative Study in Elderly Hypertension (NICS-EH)","volume":"9","author":"Kuwajima","year":"2000","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","article-title":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives","volume":"34","author":"National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) Study Group","year":"1999","journal-title":"Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS\u2014a randomized double-blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004872-200101000-00011","article-title":"Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study","volume":"19","author":"Zanchetti","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0064|cit64","first-page":"87","article-title":"Diuretics are similar to losartan on echocardiographic target-organ damage in stage I hypertension. PREVER-Treatment Study","volume":"112","author":"Bertoluci","year":"2019","journal-title":"Arquivos Brasileiros de Cardiologia"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0065|cit65","first-page":"53","article-title":"A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial","volume":"12","author":"Fuchs","year":"2011","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/HJH.0000000000000837","article-title":"Effectiveness of chlorthalidone\/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial","volume":"34","author":"Fuchs","year":"2016","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/HJH.0b013e32832be593","article-title":"Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial","volume":"27","author":"Schmieder","year":"2009","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-Term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08037050310009545","article-title":"Treatment of isolated systolic hypertension: the SHELL study results","volume":"12","author":"Malacco","year":"2003","journal-title":"Blood Pressure"},{"issue":"9","key":"10.1002\/14651858.CD008161.pub3-BIB0070|cit70","first-page":"374","article-title":"Amlodipine and hydrochlorothiazide for isolated systolic hypertension in the Thai elderly","volume":"57","author":"Tresukosol","year":"2005","journal-title":"Siriraj Medical Journal"},{"issue":"16","key":"10.1002\/14651858.CD008161.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/jama.1982.03330160052024","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy","volume":"248","author":"Freis","year":"1982","journal-title":"JAMA"},{"issue":"3A","key":"10.1002\/14651858.CD008161.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/0002-9343(91)90431-V","article-title":"Veterans Administration Cooperative Study Group on Hypertensive Agents: effects of age on treatment results","volume":"90","author":"Freis","year":"1991","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0073|cit73","first-page":"1008","article-title":"Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV: effect on plasma glucose and glucose tolerance","volume":"7","author":"Ramirez","year":"1985","journal-title":"Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD008161.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004872-199715110-00019","article-title":"Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators","volume":"15","author":"Rosei","year":"1997","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","article-title":"The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness","volume":"16","author":"Zanchetti","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archinternmed.2011.1391","article-title":"Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial","volume":"172","author":"Hajjar","year":"2012","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jgs.12100","article-title":"Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial","volume":"61","author":"Hajjar","year":"2013","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2318-9-48","article-title":"The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition","volume":"9","author":"Hajjar","year":"2009","journal-title":"BMC Geriatrics"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0081|cit81","unstructured":"The antihypertensives and vascular, endothelial and cognitive function trial clinicaltrials.gov\/show\/NCT00605072"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0082|cit82","first-page":"530","article-title":"Results of a double-blind randomized study comparing chlorthalidone and hydrochlorothiazide combined with the new angiotensin receptor blocker azilsartan medoxomil in primary hypertension","volume":"12","author":"Bakris","year":"2010","journal-title":"Journal of Clinical Hypertension"},{"issue":"535","key":"10.1002\/14651858.CD008161.pub3-BIB0083|cit83","first-page":"136","article-title":"A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2 diabetes","volume":"57","author":"Bebb","year":"2007","journal-title":"British Journal of General Practice"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00005344-200411000-00002","article-title":"Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function","volume":"44","author":"Caruso","year":"2004","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0085|cit85","first-page":"S44","article-title":"A randomized prospective study to compare the effects of three anti-hypertensives on plasma adipokines and arterial stiffness","volume":"26","author":"Cho","year":"2008","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"Ogihara","year":"2014","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.hjh.0000166853.26087.22","article-title":"Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region","volume":"23","author":"Black","year":"2005","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.37.1.12","article-title":"Baseline characteristics and early blood pressure control in the CONVINCE trial","volume":"37","author":"Black","year":"2001","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0197-2456(98)00013-0","article-title":"Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial","volume":"19","author":"Black","year":"1998","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/HYPERTENSIONAHA.109.139592","article-title":"Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications","volume":"55","author":"Cooper-DeHoff","year":"2010","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","article-title":"Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial","volume":"29","author":"Matsuzaki","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD008161.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7150\/ijms.9026","article-title":"Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in renin-angiotensin system (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (Combination strategy on renal function of benidipine or diuretics treatment with RAS inhibitors in a chronic kidney disease hypertensive population) Study","volume":"11","author":"Ando","year":"2014","journal-title":"International Journal of Medical Sciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008161.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000049095","article-title":"A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension","volume":"96","author":"Ebbs","year":"2001","journal-title":"Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.jhh.1001637","article-title":"Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study","volume":"18","author":"Galzerano","year":"2004","journal-title":"Journal of Human Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/HJH.0b013e32832f4fae","article-title":"CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men","volume":"27","author":"Donner","year":"2009","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjhyper.2006.09.006","article-title":"Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study)","volume":"20","author":"Hiltunen","year":"2007","journal-title":"American Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/FPC.0b013e328338e1b8","article-title":"Common genetic variation of beta1-and beta2-adrenergic receptor and response to four classes of antihypertensive treatment","volume":"20","author":"Suonsyrja","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/08037050600963669","article-title":"Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes","volume":"15","author":"Grassi","year":"2006","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0100|cit100","first-page":"54","article-title":"Electrolyte effects during initiation of antihypertensive therapy with amlodipine or hydrochlorothiazide in diabetic Nigerians","volume":"115","author":"Iyalomhe","year":"2014","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"issue":"3","key":"10.1002\/14651858.CD008161.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/2042018812445573","article-title":"Antihypertensive treatment in patients with class 3 obesity","volume":"3","author":"Jordan","year":"2012","journal-title":"Therapeutic Advances in Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0102|cit102","first-page":"583","article-title":"To study the efficacy of losartan on urinary uric acid excretion in thiazide induced hyperuricemic and hypertensive patients","volume":"24","author":"Khan","year":"2011","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008161.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.22442\/jlumhs.08720168","article-title":"Safety of losartan in hypertensive patients with thiazide induced hyperuricemia","volume":"7","author":"Khan","year":"2008","journal-title":"Journal of the Liaquat University of Medical and Health Sciences"},{"issue":"18","key":"10.1002\/14651858.CD008161.pub3-BIB0104|cit104","first-page":"416","article-title":"Valsartan but not a thiazide improves aortic augmentation pressure index in essential hypertension: a randomized, placebo controlled study","volume":"102","author":"Klingbeil","year":"2000","journal-title":"Circulation"},{"issue":"9311","key":"10.1002\/14651858.CD008161.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0106|cit106","first-page":"22","article-title":"Body mass index and cardiovascular events in patients with hypertension and left ventricular hypertrophy","volume":"23","author":"De Simone","year":"2006","journal-title":"Cardiology Review"},{"issue":"Spec Iss 2","key":"10.1002\/14651858.CD008161.pub3-BIB0107|cit107","first-page":"2HS13","article-title":"Management of cardiovascular risk in patients with left ventricular hypertrophy. [French]","volume":"31","author":"Ambrosioni","year":"2002","journal-title":"Presse Medicale"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00004872-200301000-00032","article-title":"Regression of left ventricular hypertrophy with echocardiography: some lessons from the live study","volume":"21","author":"Gosse","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00004872-199816040-00015","article-title":"Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension","volume":"16","author":"Gosse","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200018100-00015","article-title":"Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study","volume":"18","author":"Gosse","year":"2000","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0111|cit111","first-page":"274","article-title":"Central aortic pressure is a better determinant of anti-hypertensive response than brachial pressure in young hypertensive patients","volume":"68","author":"Mahmud","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.amjhyper.2003.11.001","article-title":"Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril\/indapamide first-line combination in hypertensive patients: the REASON study","volume":"17","author":"Chamontin","year":"2004","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1524-6175.2002.00493.x","article-title":"Psychological characteristics and responses to antihypertensive drug therapy","volume":"4","author":"Mann","year":"2002","journal-title":"Journal of Clinical Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.amjhyper.2003.09.012","article-title":"Effect of different antihypertensive drug classes on central aortic pressure","volume":"17","author":"Morgan","year":"2004","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1993.03510060059034","article-title":"Treatment of mild hypertension study: final results","volume":"270","author":"Neaton","year":"1993","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/HJH.0b013e3283410390","article-title":"A functional variant of the NEDD4L gene is associated with beneficial treatment response with \u03b2-blockers and diuretics in hypertensive patients","volume":"29","author":"Svensson-Farbom","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0118|cit118","first-page":"18","article-title":"The activity of nonspecific inflammation in hypertensive patients","volume":"79","author":"Oshchepkova","year":"2007","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0119|cit119","first-page":"S24","article-title":"Clinical predictors of dysglycemic effects associated with use of beta blockers and thiazide diuretics","volume":"91","author":"Moore","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/phar.1483","article-title":"Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide","volume":"34","author":"Moore","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1479-5876-10-47","article-title":"Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response","volume":"10","author":"Turner","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/HYPERTENSIONAHA.112.198721","article-title":"G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment-related outcomes in hypertension","volume":"60","author":"Vandell","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/hr.2014.148","article-title":"Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure","volume":"38","author":"Peng","year":"2015","journal-title":"Hypertension Research"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11530600-000000000-00000","article-title":"The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan\/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Pool","year":"2009","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00392-014-0755-6","article-title":"Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic","volume":"104","author":"Posadzy-Malaczynska","year":"2014","journal-title":"Clinical Research in Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3317\/jraas.2001.021","article-title":"Blood pressure and stroke; the PROGRESS trial","volume":"2","author":"He","year":"2001","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00044011-200626020-00004","article-title":"Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg\/day or 2.5 mg\/day and potassium chloride compared with enalapril 10 mg\/day and amlodipine 5 mg\/day in patients with mild to moderate primary hypertension: a multicentre, randomised, open study","volume":"26","author":"Rasmussen","year":"2006","journal-title":"Clinical Drug Investigation"},{"issue":"3","key":"10.1002\/14651858.CD008161.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio","volume":"116","author":"Hood","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.jhh.1001812","article-title":"Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial","volume":"19","author":"Schram","year":"2005","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.jhh.1002025","article-title":"Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension","volume":"20","author":"Spoelstra-de Man","year":"2006","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/ajh\/hpt047","article-title":"The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension","volume":"26","author":"Schwartz","year":"2013","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jch.12230","article-title":"Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program","volume":"16","author":"Kostis","year":"2014","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0133|cit133","first-page":"971","article-title":"Effect of chlorthalidone treatment on mortality: 20-year follow-up of the systolic hypertension in the elderly program (SHEP)","volume":"32","author":"Kostis","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1291\/hypres.23.593","article-title":"Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension","volume":"23","author":"Shionoiri","year":"2000","journal-title":"Hypertension Research - Clinical & Experimental"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/00004872-200402001-00361","article-title":"Effect of antihypertensive therapy with amlodipine or diuretic on silent cerebrovascular damage: a randomized, double blind, comparative study","volume":"22","author":"Sierra","year":"2004","journal-title":"Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008161.pub3-BIB0137|cit137","first-page":"e348","article-title":"Antihypertensive class and stroke recurrence: an analysis of the VISP trial","volume":"42","author":"Solorzano","year":"2011","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0138|cit138","first-page":"E314","article-title":"Low-dose hydrochlorothiazide monotherapy is the most effective and tolerable antihypertensive drug compared with long-acting nifedipine, atenolol, or captopril monotherapy in Chinese patients with hypertension: The SPREAD study","volume":"113","author":"Fan","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/08037050410014944","article-title":"Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2","volume":"13","author":"Ekbom","year":"2004","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008161.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/blo.9.2.17.20","article-title":"Results of the STOP-Hypertension-2 trial","volume":"9","author":"Hansson","year":"2000","journal-title":"Blood Pressure. Supplement"},{"issue":"9281","key":"10.1002\/14651858.CD008161.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","article-title":"Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial","volume":"358","author":"Lindholm","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/01.hjh.0000378603.51085.26","article-title":"Impact of medical treatment on central aortic systolic blood pressure - The MONICA\/KORA study","volume":"28","author":"Stritzke","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.0000142169.17298.54","article-title":"Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension","volume":"44","author":"Fagard","year":"2004","journal-title":"Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00004872-200312000-00012","article-title":"Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population","volume":"21","author":"Pringle","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.jhh.1000685","article-title":"Effects of losartan on hypertension and left ventricular mass: a long-term study","volume":"12","author":"Tedesco","year":"1998","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0895-7061(99)00156-9","article-title":"Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients","volume":"12","author":"Tedesco","year":"1999","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0149|cit149","first-page":"152","article-title":"Persistence and compliance to treatment with diuretics as first choice in antihypertensive therapy","volume":"18","author":"Trimarco","year":"2011","journal-title":"High Blood Pressure and Cardiovascular Prevention"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40292-014-0065-0","article-title":"Should thiazide diuretics be given as first line antihypertensive therapy or in addition to other medications?","volume":"22","author":"Trimarco","year":"2015","journal-title":"High Blood Pressure and Cardiovascular Prevention"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/dc10-1420","article-title":"Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial","volume":"34","author":"Anderson","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0152|cit152","first-page":"999","article-title":"A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice","volume":"3","author":"Veronesi","year":"2007","journal-title":"Vascular Health andRrisk Management"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jama.1963.03060110023012","article-title":"Methyldopa and hydrochlorothiazide in primary hypertension: controlled clinical trial of drugs singly and in combination","volume":"185","author":"Wilson","year":"1963","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10641963.2014.913599","article-title":"Effects of doxazosin as the third agent on morning hypertension and position-related blood pressure changes in diabetic patients with chronic kidney disease","volume":"37","author":"Yasuda","year":"2015","journal-title":"Clinical and Experimental Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0155|cit155","unstructured":"Yogiantoro M Bakri S Kabo P Efficacy and tolerability of indapamide sr 1.5 mg in mild to moderate hypertension: a double-blind study compared to amlodipine 5 mg 13th Asian Colloquium in Nephrology ~ Kartika Plaza Beach Hotel, Bali 2000 180 90"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"182S","DOI":"10.1093\/ajh\/5.6.182S","article-title":"Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial","volume":"5","author":"Yurenev","year":"1992","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0157|cit157","unstructured":"Treatment of hypertension in Tibetan adult population clinicaltrials.gov\/show\/NCT02217852"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004349.pub3","article-title":"Blood pressure targets in adults with hypertension","author":"Arguedas","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD008161.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA Versus ESC\/ESH on Hypertension Guidelines","volume":"73","author":"Bakris","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008169.pub2","article-title":"Spironolactone for hypertension","author":"Batterink","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41440-021-00666-6","article-title":"Why we need a single independent international hypertension clinical practice guideline","volume":"44","author":"Ben-Eltriki","year":"2021","journal-title":"Hypertension Research"},{"issue":"11","key":"10.1002\/14651858.CD008161.pub3-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008170.pub3","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","author":"Chen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke and coronary heart disease - part 2, short term reduction in blood pressure: overview of randomised drug trials in epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0164|cit164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006742.pub2","article-title":"Pharmacotherapy for mild hypertension","author":"Diao","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/erc.10.27","article-title":"Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics","volume":"8","author":"Duarte","year":"2010","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008161.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199000392-00004","article-title":"Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE","volume":"39","author":"Dzau","year":"1990","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0167|cit167","volume-title":"Current Cardiovascular Drugs","author":"Frishman","year":"2005"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0168|cit168","first-page":"1","article-title":"New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit","volume":"10","author":"Gueyffier","year":"1996","journal-title":"Journal of Human Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0169|cit169","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003822.pub2","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004643.pub3","article-title":"Blood pressure lowering efficacy of alpha blockers for primary hypertension","author":"Heran","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008161.pub3-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008167.pub3","article-title":"Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension","author":"Heran","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0173|cit173","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0174|cit174","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-121-5-199409010-00008","article-title":"Drug treatment of hypertension in the elderly: a meta-analysis","volume":"121","author":"Insua","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular risk and risk factors in a randomized trial of beta blocker, oxeprenolol: the International Prospective Primary Prevention study in hypertension (IPPSH)","volume":"3","author":"IPPSH Collaboration Group","year":"1985","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD008161.pub3-BIB0178|cit178","first-page":"28s","article-title":"Pharmacology and mechanisms of action of calcium-channel blockers","volume":"2","author":"Katz","year":"1986","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0179|cit179","volume-title":"Harrison's Principals of Internal Medicine","volume":"2","year":"2012"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0180|cit180","doi-asserted-by":"crossref","unstructured":"Lundh A Lexchin J Mintzes B Schroll JB Bero L Industry sponsorship and research outcome Cochrane Database of Systematic Reviews 2017 2 10.1002\/14651858.MR000033.pub3","DOI":"10.1002\/14651858.MR000033.pub3"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0181|cit181","first-page":"967","article-title":"The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in the elderly hypertensives","volume":"15","author":"MacMahon","year":"1993","journal-title":"Clinical & Experimental Hypertension (New York)"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003824.pub2","article-title":"Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension","author":"Musini","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008161.pub3-BIB0183|cit183","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003825.pub4","article-title":"Blood pressure-lowering efficacy of loop diuretics for primary hypertension","author":"Musini","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008276.pub2","article-title":"Pharmacotherapy for hypertension in adults aged 18 to 59 years","author":"Musini","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000028.pub3","article-title":"Pharmacotherapy for hypertension in adults 60 years or older","author":"Musini","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008161.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/clc.4960131104","article-title":"Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism","volume":"13","author":"Nash","year":"1990","journal-title":"Clinical Cardiology"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0189|cit189","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"8","key":"10.1002\/14651858.CD008161.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ajhp\/58.8.671","article-title":"Angiotensin II-receptor blockers: clinical relevance and therapeutic role","volume":"58","author":"Rodgers","year":"2001","journal-title":"American Journal of Health-system Pharmacy: AJHP"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0191|cit191","unstructured":"WebPlotDigitizer Rohatgi A Ankit Rohatgi"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.amjmed.2007.11.016","article-title":"Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug","volume":"121","author":"Shafiq","year":"2008","journal-title":"American Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008161.pub3-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1001\/jamainternmed.2018.4684","article-title":"Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension","volume":"178","author":"Sheppard","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/M14-0773","article-title":"Effects of blood pressure reduction in mild hypertension. A systematic review and meta-analysis","volume":"162","author":"Sundstr\u00f6m","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008161.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004872-199210000-00001","article-title":"A meta-analysis of outcome trials in elderly hypertensives","volume":"10","author":"Thijs","year":"1992","journal-title":"Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD008161.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: head-to-head comparisons of various classes of antihypertensive drugs--overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"Journal of Hypertension"},{"issue":"19","key":"10.1002\/14651858.CD008161.pub3-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults","volume":"71","author":"Whelton","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0199|cit199","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub3","article-title":"First-line drugs for hypertension","author":"Wright","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008161.pub3-BIB0201|cit201","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003654.pub5","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Zhu","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008161.pub3-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008161.pub2","article-title":"First-line diuretics versus other classes of antihypertensive drugs for hypertension","author":"Reinhart","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008161.pub3-BIB0203|cit203","first-page":"25","article-title":"Systematic review of anti-hypertensive therapies: does the evidence assist in choosing a first-line drug?","volume":"161","author":"Wright","year":"1999","journal-title":"Canadian Medical Association Journal"},{"issue":"4","key":"10.1002\/14651858.CD008161.pub3-BIB0204|cit204","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008161","article-title":"First-line diuretics versus other classes of antihypertensive drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T12:40:43Z","timestamp":1730292043000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008161.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":204,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008161.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}